{
    "clinical_study": {
        "@rank": "40335", 
        "arm_group": {
            "arm_group_label": "Treatment (curcumin, cholecalciferol)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive curcumin PO daily on days 1-28 and cholecalciferol PO daily on days 8-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving partial response or better may receive treatment for a total of 2 years."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies the efficacy (activity), and tolerability of curcumin and\n      cholecalciferol combination in treating patients with previously untreated stage 0-II\n      chronic lymphocytic leukemia or small lymphocytic lymphoma. Curcumin and cholecalciferol may\n      prevent or slow the growth of cancer cells."
        }, 
        "brief_title": "Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", 
        "completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Contiguous Stage II Small Lymphocytic Lymphoma", 
            "Noncontiguous Stage II Small Lymphocytic Lymphoma", 
            "Stage 0 Chronic Lymphocytic Leukemia", 
            "Stage I Chronic Lymphocytic Leukemia", 
            "Stage I Small Lymphocytic Lymphoma", 
            "Stage II Chronic Lymphocytic Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the overall response rate (ORR) based on National Cancer Institute-Working\n      Group (NCI-WG) criteria in chronic lymphocytic leukemia (CLL) or the Cheson criteria in\n      small lymphocytic lymphoma (SLL).\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine the time to first cytotoxic treatment (TFCT), progression free survival\n      (PFS), and overall survival (OS) using this regimen.\n\n      OUTLINE:\n\n      Patients receive curcumin orally (PO) daily on days 1-28 and cholecalciferol PO daily on\n      days 8-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days\n      for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients\n      achieving partial response or better may receive treatment for a total of 2 years.\n\n      After completion of study treatment, patients are followed up for 30 days and then every 3-6\n      months for 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a diagnosis of CLL based on peripheral blood flow cytometry and/or bone marrow\n             aspiration and biopsy OR diagnosis of SLL based on lymph node or bone marrow biopsy;\n             patients with SLL need to have measurable disease\n\n          -  Performance status (Eastern Cooperative Oncology Group [ECOG]) 0-2\n\n          -  Patients must have not received any prior treatment for CLL or SLL\n\n          -  Patients must be stage 0-II based on Rai staging system; must have no indication for\n             treatment for SLL per NCI-WG criteria\n\n          -  Absolute neutrophil count (ANC) >= 1,500/mm^3\n\n          -  Platelet count >= 100,000/mm^3\n\n          -  Hemoglobin >= 10 g/dL\n\n          -  Serum creatinine =< 2.0 g/dL or calculated creatinine clearance (CrCl) >= 60mL/min\n             (Cockcroft-Gault method)\n\n          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x\n             institutional upper limit of normal (ULN)\n\n          -  Bilirubin < 2.0 x ULN, unless subject has Gilbert's disease\n\n          -  Calcium < 10.1 mg/dL (corrected to serum albumin)\n\n          -  Females will be either postmenopausal for at least 1 year or surgically sterile for\n             at least 3 months OR females of child-bearing potential must have a negative\n             pregnancy test at screening and agree to take appropriate precautions to avoid\n             pregnancy (double barrier method of birth control or abstinence) from screening\n             through 3 months after the last dose of treatment\n\n          -  Able to comprehend and willing to sign an Informed Consent Form (ICF)\n\n          -  Subjects must be off any steroids 7 days prior to the initiation of treatment\n\n          -  Subjects must be off any curcumin, tumeric, or vitamin D supplements for 14 days\n             prior to the initiation of treatment\n\n          -  Subjects must be able to take oral medications\n\n        Exclusion Criteria:\n\n          -  Presence of malignancy (other than the one treated in this study) which required\n             systemic treatment within the past 3 years\n\n          -  Any indication to start treatment for CLL based on NCI-WG criteria\n\n          -  Prior therapy for CLL/SLL\n\n          -  Subjects who are pregnant or breast-feeding; breastfeeding should be discontinued if\n             the mother is treated with curcumin\n\n          -  Concurrent medical condition which may increase the risk of toxicity, including:\n\n               -  Hypercalcemia of any cause\n\n               -  Untreated hyperparathyroidism\n\n               -  Paget's disease of bone\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situation that would limit compliance with\n             study requirements as judged by treating physician; subjects receiving antibiotics\n             that are under control may be included in the study\n\n          -  Inability to take oral medications\n\n          -  Patients receiving other investigational agent\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to curcumin or vitamin D or other agents used in this study\n\n          -  Patients on therapeutic anticoagulation, with heparin (or low-molecular weight\n             heparin), warfarin, or a direct thrombin inhibitor as the safety of concurrent\n             administration of curcumin has not been established\n\n          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral\n             therapy are ineligible"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100423", 
            "org_study_id": "CASE5913", 
            "secondary_id": [
                "NCI-2014-00266", 
                "CASE5913", 
                "P30CA043703"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (curcumin, cholecalciferol)", 
                "description": "Given PO", 
                "intervention_name": "curcumin", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "C.I. 75300", 
                    "C.I. Natural Yellow 3", 
                    "CU", 
                    "Diferuloylmethane"
                ]
            }, 
            {
                "arm_group_label": "Treatment (curcumin, cholecalciferol)", 
                "description": "Given PO", 
                "intervention_name": "cholecalciferol", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "Calciol", 
                    "Vitamin D3"
                ]
            }, 
            {
                "arm_group_label": "Treatment (curcumin, cholecalciferol)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment (curcumin, cholecalciferol)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Vitamins", 
                "Curcumin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 27, 2014", 
        "location": {
            "contact": {
                "email": "basem.william@uhhospitals.org", 
                "last_name": "Basem M. William", 
                "phone": "216-983-4753"
            }, 
            "facility": {
                "address": {
                    "city": "Cleveland", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "44106-5065"
                }, 
                "name": "Case Comprehensive Cancer Center"
            }, 
            "investigator": {
                "last_name": "Basem M. William", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients With Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)", 
        "overall_official": {
            "affiliation": "Case Comprehensive Cancer Center", 
            "last_name": "Basem William", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The point estimate of the overall response rate and biologic response rate along with 95% confidence intervals will be calculated using binomial distribution theory.", 
            "measure": "Overall response rate (biologic response rate + complete response [CR] + partial response [PR]) based on NCI-WG (for CLL) and Cheson criteria (for SLL)", 
            "safety_issue": "No", 
            "time_frame": "The time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100423"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Kaplan-Meier method and Cox proportional hazard model will be used for the data analysis.", 
                "measure": "Time to first cytotoxic treatment", 
                "safety_issue": "No", 
                "time_frame": "Time from entry onto study until initiation of treatment with cytotoxic agents because of disease progression, assessed up to 2 years"
            }, 
            {
                "description": "Kaplan-Meier method and Cox proportional hazard model will be used for the data analysis.", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Time from entry onto study until CLL/SLL progression or death from any cause, assessed up to 2 years"
            }, 
            {
                "description": "Kaplan-Meier method and Cox proportional hazard model will be used for the data analysis.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "source": "Case Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Case Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}